A Case of Hepatitis after Intravesical BCG Immunotherapy

2010 ◽  
Vol 23 (2) ◽  
pp. 67-69
Author(s):  
Serife Akalin ◽  
Selmin Caylak ◽  
Demet Okke ◽  
Huseyin Turgut
Keyword(s):  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Disseminated BCG Infection after intravesical BCG Immunotherapy of Bladder Cancer

QJM ◽  
2021 ◽  
Author(s):  
S Ramalingam ◽  
K Gunasekaran ◽  
H Arora ◽  
M Muruganandam ◽  
S Nagaraju ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

Histopathology of Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Immunotherapy for Urothelial Carcinoma

2015 ◽  
Vol 23 (3) ◽  
pp. 189-195 ◽  
Author(s):  
Brandon T. Larsen ◽  
Maxwell L. Smith ◽  
Thomas E. Grys ◽  
Holenarasipur R. Vikram ◽  
Thomas V. Colby
Keyword(s):  
Urothelial Carcinoma ◽  
Mycobacterium Bovis ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer

1993 ◽  
Vol 150 (3) ◽  
pp. 1018-1023 ◽  
Author(s):  
Timothy L. Ratliff ◽  
Julie K. Ritchey ◽  
Jerry J.J. Yuan ◽  
Gerald L. Andriole ◽  
William J. Catalona
Keyword(s):  
Bladder Cancer ◽  
T Cell ◽  
T Cell Subsets ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy

2021 ◽  
Vol 8 ◽  
Author(s):  
Zheng Liu ◽  
Gongwei Long ◽  
Yucong Zhang ◽  
Guoliang Sun ◽  
Wei Ouyang ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Cox Regression ◽  
Recurrence Risk ◽  
Perioperative Outcomes ◽  
Thulium Laser ◽  
Bladder Tumors ◽  
Laser Resection ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg ◽  
Muscle Invasive

Background: Thulium laser resection of bladder tumors (TmLRBT) is recently considered as a common treatment option for non-muscle-invasive bladder cancers (NMIBC), but whether it is superior to Transurethral resection of bladder tumors (TURBT) are still undetermined.Materials and Methods: We retrospectively screened our institution database to identify patients who were treated by conventional TURBT or TmLRBT for NMIBC and followed by intravesical bacillus Calmette-Guérin (BCG) immunotherapy. The preoperative characteristics, perioperative outcomes, and recurrence-free survival were compared to assess the safety and efficacy of the two procedures.Results: Eventually, 90 patients who underwent TmLRBT (n = 37) or TURBT (n = 53) followed by intravesical BCG immunotherapy were included. Two groups were similar in baseline characteristics except for the smaller tumor size of the TmLRBT group(1.7 cm vs. 2.2 cm; P = 0.036). Obturator nerve reflex occurred in eight patients in the TURBT group and 3 of them suffered from bladder perforation while none happened in the TmLRBT group. The TmLRBT also had a shorter irrigation duration. In the multivariate Cox regression, the TmLRBT was related to less recurrence risk (HR: 0.268; 95% CI, 0.095–0.759; P = 0.013).Conclusion: Our results suggested that TmLRBT is safer than conventional TURBT with fewer perioperative complications, and it offers better cancer control, therefore might be a superior option for NMIBC patients with intermediate and high recurrence risk.

scholarly journals Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Yuqing Liu ◽  
Jian Lu ◽  
Yi Huang ◽  
Lulin Ma
Keyword(s):  
Bladder Cancer ◽  
Adverse Reactions ◽  
Clinical Manifestations ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Proven Efficacy ◽  
Bcg Instillation ◽  
Early Establishment

Because of its proven efficacy, intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or progression. However, approximately 8% of patients have to stop BCG instillation as a result of its complications. Complications induced by BCG therapy can have a variety of clinical manifestations. These adverse reactions may occur in conjunction with BCG instillation or may not develop until months or years after BCG cessation. An essential step in the management complications arising from BCG is early establishment of diagnosis, particularly for distant, disseminated, and obscure infections. Therefore we reviewed the literature on the potential complications after intravesical BCG immunotherapy for bladder cancer and provide an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications.

Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: A case report

1995 ◽  
Vol 27 (3) ◽  
pp. 307-310 ◽  
Author(s):  
A. Erol ◽  
S. Özgür ◽  
N. Tahtali ◽  
E. Akbay ◽  
I. Dalva ◽  
...  
Keyword(s):  
Case Report ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

CASE REPORT Reactive arthritis after application of intravesical BCG immunotherapy in bladder cancer

2009 ◽  
Vol 62 ◽  
pp. 266-267
Author(s):  
Artur Chmiel ◽  
Joanna Wierzbicka-Chmiel ◽  
Krzysztof Wierzbicki ◽  
Tadeusz Dzielski ◽  
Jolanta Gil
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Reactive Arthritis ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg
Sign in / Sign up

Export Citation Format

Share Document